T. Rowe Price Associates
AMRX icon

T. Rowe Price Associates’s Amneal Pharmaceuticals AMRX Stock Holding History

T. Rowe Price Associates’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4M Buy
230,997
+48,056
+26% +$659K ﹤0.01% 1674
2026
Q1 		$2.27M Buy
182,941
+38,237
+26% +$513K ﹤0.01% 1774
2025
Q4 		$1.82M Buy
144,704
+7,015
+5% +$80.3K ﹤0.01% 1795
2025
Q3 		$1.38M Buy
137,689
+7,040
+5% +$63.2K ﹤0.01% 1910
2025
Q2 		$1.06M Buy
130,649
+3,973
+3% +$30K ﹤0.01% 1964
2025
Q1 		$1.06M Buy
126,676
+29,426
+30% +$246K ﹤0.01% 1929
2024
Q4 		$771K Buy
97,250
+9,704
+11% +$81.4K ﹤0.01% 2086
2024
Q3 		$729K Buy
87,546
+1,519
+2% +$11.9K ﹤0.01% 2097
2024
Q2 		$547K Buy
86,027
+4,763
+6% +$30.2K ﹤0.01% 2158
2024
Q1 		$493K Buy
81,264
+5,146
+7% +$29K ﹤0.01% 2217
2023
Q4 		$463K Buy
76,118
+1,949
+3% +$8.68K ﹤0.01% 2210
2023
Q3 		$313K Buy
74,169
+2,361
+3% +$8.8K ﹤0.01% 2314
2023
Q2 		$223K Buy
71,808
+51,989
+262% +$111K ﹤0.01% 2483
2023
Q1 		$28K Buy
19,819
+2,203
+13% +$4.39K ﹤0.01% 2835
2022
Q4 		$35K Buy
17,616
+525
+3% +$1.18K ﹤0.01% 2851
2022
Q3 		$35K Buy
+17,091
New +$47.9K ﹤0.01% 2873
2019
Q4 		– Sell
-11,283,585
Closed -$32.7M – 2528
2019
Q3 		$32.7M Sell
11,283,585
-7,382,540
-40% -$25.8M ﹤0.01% 1011
2019
Q2 		$134M Sell
18,666,125
-1,195,293
-6% -$12.2M 0.02% 570
2019
Q1 		$281M Buy
19,861,418
+239,722
+1% +$3.17M 0.04% 378
2018
Q4 		$265M Buy
19,621,696
+8,551,192
+77% +$154M 0.04% 361
2018
Q3 		$246M Buy
11,070,504
+11,027,092
+25,401% +$232M 0.04% 426
2018
Q2 		$712K Buy
+43,412
New +$762K ﹤0.01% 1992

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

T. Rowe Price Associates's AMRX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Amneal Pharmaceuticals (AMRX) stake by 26% in Q2 2026, buying an estimated $659K and bringing the position to 230,997 shares worth $4M. The position accounts for ﹤0.01% of the portfolio, ranked #1674.

T. Rowe Price Associates first reported a position in AMRX in Q2 2018 and has held it in 22 quarters since. The position peaked at $281M in Q1 2019. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • T. Rowe Price Associates held 230,997 shares of Amneal Pharmaceuticals worth $4M as of Q2 2026.
  • T. Rowe Price Associates bought 48,056 Amneal Pharmaceuticals shares in Q2 2026, an estimated $659K.
  • Amneal Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1674 holding.
  • T. Rowe Price Associates first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 22 quarters since.
  • T. Rowe Price Associates's Amneal Pharmaceuticals position peaked at $281M in Q1 2019.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.